These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37686529)

  • 1. Molecular and Clinical Characteristics of Different Toxicity Rates in Anti-CD19 Chimeric Antigen Receptor T Cells: Real-World Experience.
    Gavriilaki E; Mallouri D; Bousiou Z; Demosthenous C; Vardi A; Dolgyras P; Batsis I; Stroggyli E; Karvouni P; Masmanidou M; Gavriilaki M; Bouinta A; Bitsianis S; Kapravelos N; Bitzani M; Vasileiadou G; Yannaki E; Sotiropoulos D; Papagiannopoulos S; Kazis D; Kimiskidis V; Anagnostopoulos A; Sakellari I
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
    Wehrli M; Gallagher K; Chen YB; Leick MB; McAfee SL; El-Jawahri AR; DeFilipp Z; Horick N; O'Donnell P; Spitzer T; Dey B; Cook D; Trailor M; Lindell K; Maus MV; Frigault MJ
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34996813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
    Sesques P; Ferrant E; Safar V; Wallet F; Tordo J; Dhomps A; Karlin L; Brisou G; Vercasson M; Hospital-Gustem C; Schwiertz V; Ranchon F; Rioufol C; Choquet M; Sujobert P; Ghergus D; Bouafia F; Golfier C; Lequeu H; Lazareth A; Novelli S; Devic P; Traverse Glehen A; Viel S; Venet F; Mialou V; Hequet O; Chauchet A; Arkam Y; Nicolas-Virelizier E; Peyrade F; Cavalieri D; Ader F; Ghesquières H; Salles G; Bachy E
    Am J Hematol; 2020 Nov; 95(11):1324-1333. PubMed ID: 32744738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
    Front Immunol; 2021; 12():745320. PubMed ID: 34712233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
    Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
    Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma.
    Nie EH; Su YJ; Baird JH; Agarwal N; Bharadwaj S; Weng WK; Smith M; Dahiya S; Han MH; Dunn JE; Kipp LB; Miklos DB; Scott BJ; Frank MJ
    Blood Adv; 2024 Mar; 8(6):1474-1486. PubMed ID: 38295285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells.
    Pennisi M; Sanchez-Escamilla M; Flynn JR; Shouval R; Alarcon Tomas A; Silverberg ML; Batlevi C; Brentjens RJ; Dahi PB; Devlin SM; Diamonte C; Giralt S; Halton EF; Jain T; Maloy M; Mead E; Palomba ML; Ruiz J; Santomasso B; Sauter CS; Scordo M; Shah GL; Park JH; Yanez San Segundo L; Perales MA
    Blood Adv; 2021 Sep; 5(17):3397-3406. PubMed ID: 34432870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of long-term corticosteroids in patients treated with CAR T-cell therapy.
    Hashmi H; McGann M; Greenwell BI
    J Oncol Pharm Pract; 2023 Mar; 29(2):473-476. PubMed ID: 35635259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome.
    Lakomy T; Akhoundova D; Nilius H; Kronig MN; Novak U; Daskalakis M; Bacher U; Pabst T
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T.
    Crees ZD; Ghobadi A
    Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central Nervous System Involvement.
    Yi D; Gergis M; Elgohary G; Hsu J; Yang Y; Bi X; Gergis U
    Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):66-72. PubMed ID: 36537908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
    Halford Z; Anderson MK; Bennett LL
    Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
    Ruff MW; Siegler EL; Kenderian SS
    Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
    Freyer CW; Porter DL
    J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management.
    Pennisi M; Jain T; Santomasso BD; Mead E; Wudhikarn K; Silverberg ML; Batlevi Y; Shouval R; Devlin SM; Batlevi C; Brentjens RJ; Dahi PB; Diamonte C; Giralt S; Halton EF; Maloy M; Palomba ML; Sanchez-Escamilla M; Sauter CS; Scordo M; Shah G; Park JH; Perales MA
    Blood Adv; 2020 Feb; 4(4):676-686. PubMed ID: 32084260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.
    Qu C; Zou R; Wang P; Zhu Q; Kang L; Ping N; Xia F; Liu H; Kong D; Yu L; Wu D; Jin Z
    Front Immunol; 2022; 13():969660. PubMed ID: 36059523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapy.
    Yoo JW
    Blood Res; 2023 Apr; 58(S1):S20-S28. PubMed ID: 36891576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium.
    Jacobs MT; Jain MD; Gao F; Nastoupil LJ; Spiegel JY; Lin Y; Dahiya S; Lunning M; Lekakis L; Reagan PM; Oluwole OO; McGuirk J; Deol A; Sehgal A; Goy A; Hill BT; Andreadis C; Munoz J; Chavez JC; Bennani NN; Rapoport AP; Vose JM; Miklos DB; Neelapu SS; Ghobadi A; Locke FL
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):753-759. PubMed ID: 35780055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis.
    Meng J; Wu X; Sun Z; Xun R; Liu M; Hu R; Huang J
    Front Oncol; 2021; 11():698607. PubMed ID: 34381720
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.